AbbVie’s Rinvoq shows superiority over Humira in head-to-head arthritis study
By Thomson ReutersOct 20, 2025 | 7:12 AM
(Reuters) -AbbVie said on Monday its newer arthritis drug Rinvoq showed superiority over the company’s previous bestseller Humira, meeting the main goal of a head-to-head trial.
Comments